Clinical trials · Maryland
Cancer clinical trials in Maryland
We’re tracking 707 recruiting cancer studies with a site in Maryland — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT06138067Recruiting
Navigator program to help cancer patients join clinical trials
This study tests if a patient navigator can help more people with prostate or kidney cancer enroll in clinical trials. You may be assigned to work with a navigator who helps find a trial that fits your needs.
Baltimore, MarylandAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Baltimore, MarylandAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Aberdeen, MarylandAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Elkton, MarylandAges 18 years+ - NCT05995821Recruiting
Blood and tissue collection for head and neck cancers
This study collects blood and tissue samples from people with cancers of the head, neck, or upper airway to learn how the immune system responds to these cancers. The goal is to find better ways to treat these diseases in the future.
Baltimore, MarylandAges 18 years+ - NCT05849480RecruitingPhase 1/Phase 2
Study of CD40 treatment with CAPOX and Keytruda for bile duct cancer
This trial studies a new immune “switch” treatment called CDX-1140 combined with standard chemo (CAPOX) and Keytruda, for biliary tract cancer that can’t be cured with surgery or transplant. It’s designed for people whose cancer has progressed after first-line treatment, with the goal of improving cancer control and outcomes.
Bethesda, MarylandAges 18–120 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Gaithersburg, MarylandAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Bethesda, MarylandAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Baltimore, MarylandAges 18–100 - NCT05350761Recruiting
Study rare tumors and inherited cancer risk in families
This study looks at people who have rare or unusual cancers or who may have an inherited (family) risk for cancer. It helps researchers learn what genetic or other factors might be involved by collecting family history and medical records, including pathology slides.
Bethesda, MarylandAges Any age - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Baltimore, MarylandAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
Bethesda, MarylandAges 12 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Towson, MarylandAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Bethesda, MarylandAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Silver Spring, MarylandAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Baltimore, MarylandAges 18 years+ - NCT02594202Recruiting
Collecting prostate cancer care details and prostate tissue samples
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
Bethesda, MarylandAges 18 years+ - NCT01915225Recruiting
Collecting solid tumor samples during cancer biopsy or surgery
This trial collects tissue (samples) from people who are already scheduled for biopsy or surgery for certain solid cancers. It aims to improve future testing and research while checking that taking the sample is safe and doesn’t add extra risk.
Bethesda, MarylandAges 2 years+ - NCT00001238Recruiting
Understanding kidney cancer genes in families
This research study helps doctors understand inherited kidney cancers and related conditions that run in families. Researchers collect medical information and blood samples to identify genetic causes and improve how these conditions are diagnosed and treated.
Bethesda, MarylandAges 2 years+ - NCT00026884Recruiting
Blood and tissue sample collection for cancer research
This study collects blood and tissue samples from people with cancer or suspected cancer, or from their blood relatives. Researchers use these samples to better understand cancer and develop new treatments.
Bethesda, MarylandAges 2 years+
Cancer trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting cancer studies listed above.
- National Institutes of Health Clinical Center · 8 studies
- Johns Hopkins University · 4 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 3 studies
- Frederick Health - James M Stockman Cancer Institute · 2 studies
- Sinai Hospital of Baltimore · 2 studies
- University of Maryland Baltimore Washington Medical Center · 2 studies
- University of Maryland/Greenebaum Cancer Center · 2 studies
- Walter Reed National Military Medical Center · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Maryland?
- Yes. We're currently tracking 707 recruiting cancer studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.